Poseida Therapeutics, Inc.
NEWS
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day.
It was a relatively quiet week for clinical trial news. Here’s a look.
Shares of Poseida Therapeutics plunged more than 20% in premarket trading this morning after the company announced the U.S. Food and Drug Administration halted a cancer drug trial due to safety concerns.
The company is focused on developing cell and gene therapies based on a proprietary DNA modification, gene editing and delivery technology.
Swiss pharma giant Novartis supported the company’s Series C financing round with a $75 million equity investment.
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
JOBS
IN THE PRESS